LeonaBio Inc LONA

Morningstar Rating
$2.02 −0.44 (17.89%)
View Full Chart

About Quantitative Ratings

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.

Price vs Fair Value

LONA is trading within a range we consider fairly valued.
Price
$2.46
Fair Value
LOCK|&?>Jsr
Uncertainty
LOCK|yh F$VZ
1-Star Price
LOCK|.Q@t&Fy<
5-Star Price
LOCK|vkldQQ
Economic Moat
LOCK|KJ$RF
Capital Allocation
—

News

Trading Information

Previous Close Price
$2.46
Day Range
$1.91–2.49
52-Week Range
$1.91–14.21
Bid/Ask
$1.97 / $1.98
Shares Outstanding
13.08M
Market Cap
$26.41M
Volume/Avg
68,874 / 189,850

Key Statistics

Price/Earnings (Normalized)
—
Price/Sales
—
Dividend Yield (Trailing)
0.00%
Dividend Yield (Forward)
0.00%
Dividend Payment Schedule
—
Total Yield
—

Company Profile

LeonaBio Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for high unmet medical needs. Its key drug candidates, lasofoxifene and ATH-1105, are novel, small-molecule therapies with the potential to address treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis (ALS). LeonaBio is also exploring the use of other drug candidates that enhance the neurotrophic HGF system, including ATH-1020, to improve neuronal health and function in multiple neurological diseases. In addition, it is also focused on designing and testing new early compounds directed towards novel targets for a variety of clinical applications. The company operates as a single operating segment, developing and commercializing therapeutics.
Sector
Healthcare
Industry
Biotechnology
Stock Style Box
Small Value
Total Number of Employees
19

Valuation

Metric
LONA
Price/Earnings (Normalized)
—
Price/Book Value
1.25
Price/Sales
—
Price/Cash Flow
—
Price/Earnings
No chart available

Financial Strength

Metric
LONA
Quick Ratio
4.41
Current Ratio
4.96
Interest Coverage
—
Quick Ratio
LONA

Profitability

Metric
LONA
Return on Assets (Normalized)
−100.64%
Return on Equity (Normalized)
−189.36%
Return on Invested Capital (Normalized)
−185.21%
Return on Assets
LONA

Biotechnology Industry Comparables

1-Day Chart
Name
Price
Morningstar Rating for Stocks
Capital Allocation
Economic Moat
Market Cap
Vertex Pharmaceuticals Inc
VRTX
LOCK|FTwv>$LOCK|^%GL$131B
Regeneron Pharmaceuticals Inc
REGN
LOCK|JCJ$?dzLOCK|%@?H$95B
Moderna Inc
MRNA
LOCK|$<RV?#HLOCK|j?$79B
argenx SE ADR
ARGX
LOCK|x^%Cy$WLOCK|@!>$59B
BeOne Medicines Ltd ADR
ONC
LOCK|KyzQl&DLOCK|^%N$45B
Royalty Pharma PLC Class A
RPRX
LOCK|ZCNXg#%rLOCK|y!?s$30B
Incyte Corp
INCY
LOCK|Lr&Bm!LOCK|fT&$23B
BioNTech SE ADR
BNTX
LOCK|@<v@dMLOCK|d>?$20B
Alnylam Pharmaceuticals Inc
ALNY
LOCK|!>%Gm!RLOCK|><jv>$19B
BridgeBio Pharma Inc
BBIO
LOCK|!yDRLlLOCK|<N$15B

Sponsor Center